Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2021

01-03-2021 | Fibromatosis | Sarcoma

The Landmark Series: Desmoid

Authors: Marco Fiore, MD, FACS, Aimee Crago, MD, FACS, Rebecca Gladdy, MD, PhD, FRCSC, FACS, Bernd Kasper, MD, PhD

Published in: Annals of Surgical Oncology | Issue 3/2021

Login to get access

Abstract

Desmoid-type fibromatosis represents a challenge in the landscape of surgical oncology, for several reasons. The tumors can be infiltrative and locally aggressive, surgery may be morbid, and patients are usually young, and thus treatment sequelae must be managed for decades. Desmoids do not have metastatic potential, therefore management strategies for desmoids have evolved to employ frontline treatments that are largely non-operative. In fact, with unpredictable and benign behavior, we now recognize that desmoids can also stabilize and regress, making active observation an option for many patients. Moreover, many medical therapies are active in the disease. We reviewed landmark studies describing contemporary issues that affect treatment recommendations for desmoid patients: prognostic factors, indication to active surveillance, role of surgical margins, postoperative radiotherapy, and the most recent expert consensus papers.
Literature
1.
WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th Edition. Lyon: International Agency for Research on Cancer; 2020.
2.
Fiore M, Rimareix F, Mariani L et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009;16:2587–2593.PubMedCrossRef
3.
Bonvalot S, Eldweny H, Haddad V et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008;34:462–468.PubMedCrossRef
4.
Timbergen MJM, Schut AW, Grunhagen DJ, Sleijfer S, Verhoef C. Active surveillance in desmoid-type fibromatosis: a systematic literature review. Eur J Cancer 2020;137:18–29.PubMedCrossRef
5.
Penel N, Le Cesne A, Bonvalot S et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer 2017;83:125–131.PubMedCrossRef
6.
Merchant NB, Lewis JJ, Woodruff JM, Leung DH, Brennan MF. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 1999;86:2045–2052.PubMedCrossRef
7.
Gronchi A, Casali PG, Mariani L et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003;21:1390–1397.PubMedCrossRef
8.
Lev D, Kotilingam D, Wei C et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007;25:1785–1791.PubMedCrossRef
9.
Huang K, Fu H, Shi Y, Zhou Y, Du C. Prognostic factors for extra-abdominal and abdominal wall desmoids: A 20-year experience at a single institution. J Surg Oncol 2009;100:563–569.PubMedCrossRef
10.
Salas S, Dufresne A, Bui B et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011;29:3553–3558.PubMedCrossRef
11.
Mullen JT, Delaney TF, Kobayashi WK et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol 2012;19:4028–4035.PubMedCrossRef
12.
13.
van Broekhoven DL, Verhoef C, Elias SG et al. Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg 2013;100:1214–1219.PubMedCrossRef
14.
Cates JM, Stricker TP. Surgical resection margins in desmoid-type fibromatosis: a critical reassessment. Am J Surg Pathol 2014;38:1707–1714.PubMedCrossRef
15.
Janssen ML, van Broekhoven DL, Cates JM et al. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg 2017;104:347–357.PubMedCrossRef
16.
Baumert BG, Spahr MO, Von Hochstetter A et al. The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiat Oncol 2007;2:12.PubMedPubMedCentralCrossRef
17.
Bertani E, Testori A, Chiappa A et al. Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations. World J Surg Oncol 2012;10:184.PubMedPubMedCentralCrossRef
18.
Eastley N, Aujla R, Silk R, Richards CJ, McCulloch TA, Esler CP, Ashford RU. Extra-abdominal desmoid fibromatosis–a sarcoma unit review of practice, long term recurrence rates and survival. Eur J Surg Oncol 2014;40:1125–1130.PubMedCrossRef
19.
Ihalainen HR, Koljonen V, Bohling TO, Tukiainen EJ, Sampo MM. The desmoid tumour: local control after surgical treatment. J Plast Surg Hand Surg 2015;49:19–24.PubMedCrossRef
20.
Kriz J, Eich HT, Haverkamp U, Seegenschmiedt MH, Heide J, Bruns F, Micke O. Radiotherapy is effective for desmoid tumors (aggressive fibromatosis)—long-term results of a German multicenter study. Oncol Res Treat 2014;37:255–260.PubMedCrossRef
21.
Pignatti G, Barbanti-Brodano G, Ferrari D et al. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop Relat Res 2000;375:207–213.CrossRef
22.
Prodinger PM, Rechl H, Keller M, Pilge H, Salzmann M, von Eisenhart-Rothe R, Holzapfel BM. Surgical resection and radiation therapy of desmoid tumours of the extremities: results of a supra-regional tumour centre. Int Orthop 2013;37:1987–1993.PubMedPubMedCentralCrossRef
23.
Stoeckle E, Coindre JM, Longy M et al. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. Eur J Surg Oncol 2009;35:129–134.PubMedCrossRef
24.
Wang CP, Chang YL, Ko JY, Cheng CH, Yeh CF, Lou PJ. Desmoid tumor of the head and neck. Head Neck 2006;28:1008–1013.PubMedCrossRef
25.
Wilkinson MJ, Chan KE, Hayes AJ, Strauss DC. Surgical outcomes following resection for sporadic abdominal wall fibromatosis. Ann Surg Oncol 2014;21:2144–2149.PubMedCrossRef
26.
Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer 2020;127:96–107.CrossRef
27.
Keus RB, Nout RA, Blay JY, et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis: an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol 2013;24:2672–2676.PubMedCrossRef
28.
Crago AM, Chmielecki J, Rosenberg M et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer 2015;54:606–615.PubMedPubMedCentralCrossRef
29.
Lazar AJ, Tuvin D, Hajibashi S et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008;173:1518–1527.PubMedPubMedCentralCrossRef
30.
31.
32.
Salas S, Chibon F, Noguchi T et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer 2010;49:560–568.PubMed
33.
Nishida Y, Tsukushi S, Urakawa H, Hamada S, Kozawa E, Ikuta K, et al. Simple resection of truncal desmoid tumors: a case series. Oncol Lett 2016; 12:1564–1568.PubMedPubMedCentralCrossRef
34.
35.
Mussi CE, Colombo P, Lo Russo C et al. Sporadic desmoid tumors of the abdominal wall: the results of surgery. Tumori 2016;102:582–587.PubMedCrossRef
36.
van Broekhoven DL, Verhoef C, Grunhagen DJ et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol 2015;22:1464–1470.PubMedCrossRef
37.
Colombo C, Miceli R, Lazar AJ et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 2013;119:3696–3702.PubMedCrossRef
38.
Heinrich MC, McArthur GA, Demetri GD et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24:1195–1203.PubMedCrossRef
39.
Penel N, Le Cesne A, Bui BN et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011;22:452–457.PubMedCrossRef
40.
Kasper B, Gruenwald V, Reichardt P et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer 2017;76:60–67.PubMedCrossRef
41.
Toulmonde M, Pulido M, Ray-Coquard I et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol 2019;20:1263–1272.PubMedCrossRef
42.
43.
44.
Gronchi A, Colombo C, Le Pechoux C et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm: a position paper from the Italian and the French Sarcoma Group. Ann Oncol 2014;25:578–583.PubMedCrossRef
45.
Kasper B, Baumgarten C, Bonvalot S et al. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise—a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer 2015;51:127–136.PubMedCrossRef
46.
Kasper B, Baumgarten C, Garcia J et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol 2017;28:2399–2408.PubMedPubMedCentralCrossRef
47.
Penel N, Coindre JM, Bonvalot S et al. Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France. Eur J Cancer 2016;58:90–96.PubMedCrossRef
48.
van Broekhoven DL, Deroose JP, Bonvalot S, Gronchi A, Grunhagen DJ, Eggermont AM, et al. Isolated limb perfusion using tumour necrosis factor alpha and melphalan in patients with advanced aggressive fibromatosis. Br J Surg 2014;101:1674–1680.PubMedCrossRef
49.
Gounder MM, Maddux L, Paty J, Atkinson TM. Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. Cancer 2020;126:531–539.PubMedCrossRef
50.
Orbach D, Brennan B, Bisogno G et al. The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series. Lancet Child Adolesc Health 2017;1:284–292.PubMedCrossRef
51.
Skapek SX, Anderson JR, Hill DA et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study. Pediatr Blood Cancer 2013;60:1108–1112.PubMedCrossRef
52.
Fiore M, Coppola S, Cannell AJ et al. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg 2014;259:973–978.PubMedCrossRef
53.
Improta L, Tzanis D, Bouhadiba T, Abdelhafidh K, Bonvalot S. Desmoid tumours in the surveillance era: what are the remaining indications for surgery? Eur J Surg Oncol 2020;46:1310–1314.PubMedCrossRef
Metadata
Title
The Landmark Series: Desmoid
Authors
Marco Fiore, MD, FACS
Aimee Crago, MD, FACS
Rebecca Gladdy, MD, PhD, FRCSC, FACS
Bernd Kasper, MD, PhD
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 3/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09395-5

Other articles of this Issue 3/2021

Annals of Surgical Oncology 3/2021 Go to the issue

ASO Author Reflections

ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma

ASO Author Reflections

ASO Author Reflections: Kidney Function After Retroperitoneal Sarcoma Resection with Nephrectomy

Breast Oncology

Does Failure to Achieve Pathologic Complete Response with Neoadjuvant Chemotherapy Identify Node-Negative Patients Who Would Benefit from Postmastectomy Radiation or Regional Nodal Irradiation?

Translational Research

Oncologic Outcomes of Robotic Radical Hysterectomy (RRH) for Patients with Early-Stage Cervical Cancer: Experience at a Referral Cancer Center

Pancreatic Tumors

Radiographic Splenic Artery Involvement Is a Poor Prognostic Factor in Upfront Surgery for Patients with Resectable Pancreatic Body and Tail Cancer

ASO Author Reflections

ASO Author Reflections: Ultrasound Assessment of the Lymphatic Drainage Area in Melanoma Patients With In-Transit Metastases